Flavonoid Isoquercitrin Shields Gut From Ischemia-Reperfusion Damage via Microbiome and NLRP3
Isoquercitrin activates Nrf2/HO-1 antioxidant signaling, suppresses NLRP3 inflammasome, and restores gut microbiome diversity to dramatically reduce intestinal injury.
Summary
Intestinal ischemia-reperfusion (II/R) injury carries 50–90% mortality and lacks effective drug treatments. Researchers tested isoquercitrin (IQ), a quercetin-derived flavonoid found in common foods, in mouse II/R models and intestinal cell lines. IQ pretreatment reinforced the intestinal barrier, reduced epithelial necrosis and villus loss, and restored microbial diversity including beneficial bacteria. Mechanistically, IQ reduced reactive oxygen species and malondialdehyde while boosting glutathione ratios and SOD activity. It activated the Nrf2/HO-1 antioxidant pathway and suppressed the NLRP3 inflammasome, cutting downstream inflammatory cytokines including Caspase-1, IL-1β, IL-6, and KC. Blocking Nrf2 with ML385 or siRNA abolished IQ's benefits, confirming this pathway as central. These findings suggest IQ could be a safe, accessible therapeutic candidate for a highly lethal surgical emergency.
Detailed Summary
Intestinal ischemia-reperfusion (II/R) injury occurs when blood flow is interrupted and then restored to the gut—a scenario common in trauma, hemorrhagic shock, bowel obstruction, organ transplantation, and aortic surgery. The reperfusion phase paradoxically worsens damage through oxidative burst and inflammatory cascades, leading to epithelial necrosis, villus destruction, barrier failure, and systemic inflammatory response syndrome. Mortality ranges from 50 to 90%, and no pharmaceutical agent has proven reliably effective in clinical settings.
This study used a combined network pharmacology and experimental approach to investigate isoquercitrin (IQ), a monoglucoside derivative of quercetin naturally abundant in herbs, vegetables, and traditional medicines. Network pharmacology analysis—drawing on SwissTarget, GeneCards, OMIM, and DrugBank databases—identified overlapping drug-disease targets and implicated redox-related and NLRP3 inflammasome pathways as key nodes. Molecular docking confirmed strong binding affinity of IQ to core target proteins. In vivo, adult male C57BL/6 mice underwent superior mesenteric artery ligation for 45 minutes followed by 2 hours of reperfusion, with IQ administered intraperitoneally at 10, 20, or 40 mg/kg for four days prior. In vitro, IEC-6 and Caco-2 intestinal epithelial cells underwent oxygen-glucose deprivation and reoxygenation (OGD/R) with IQ co-treatment.
Key results showed IQ dose-dependently preserved intestinal barrier integrity, reducing villus destruction and epithelial necrosis on histology. IQ lowered intestinal wet-to-dry weight ratios (a marker of edema) and restored expression of tight junction proteins including ZO-1 and occludin. Gut microbiota 16S rRNA sequencing revealed that II/R significantly disrupted microbial diversity and community composition; IQ pretreatment restored alpha and beta diversity and increased populations of beneficial bacteria while suppressing pathogenic taxa. On the oxidative stress front, IQ reduced ROS and malondialdehyde (MDA) levels while increasing GSH/GSSG ratios and superoxide dismutase (SOD) activity. Nuclear translocation of Nrf2 and expression of its downstream target HO-1 increased in a dose-dependent manner with IQ treatment. Critically, these antioxidant effects were abolished when Nrf2 was pharmacologically inhibited with ML385 or knocked down using siRNA, establishing Nrf2/HO-1 activation as mechanistically essential. IQ also suppressed the NLRP3 inflammasome and its downstream effectors—Caspase-1, IL-1β, IL-6, and keratinocyte-derived cytokine (KC)—indicating that IQ's antioxidant effects and NLRP3 inhibition are linked through Nrf2-mediated ROS control.
The clinical implications are notable: IQ is inexpensive, found in common dietary sources, FDA-approved as a food additive in enzymatically modified form (EMIQ), and has a well-established safety profile. Taken together, the findings provide a mechanistic rationale for testing IQ as a prophylactic or adjunctive therapy in high-risk surgical patients. Important caveats remain, including the exclusively male, single-strain mouse model and absence of human pharmacokinetic data, which limit direct translation.
Key Findings
- IQ pretreatment preserved intestinal villus architecture and reduced epithelial necrosis in a mouse II/R model in a dose-dependent manner.
- IQ restored gut microbiome diversity and increased beneficial bacterial populations disrupted by ischemia-reperfusion injury.
- IQ reduced ROS and MDA while boosting GSH/GSSG ratios and SOD activity, demonstrating potent antioxidant action.
- IQ activated Nrf2 nuclear translocation and HO-1 expression; Nrf2 inhibition (ML385/siNrf2) abolished all protective effects.
- IQ suppressed NLRP3 inflammasome activation and downstream cytokines Caspase-1, IL-1β, IL-6, and KC in both animal and cell models.
Methodology
Male C57BL/6 mice underwent superior mesenteric artery ligation (45 min ischemia, 2 h reperfusion) with 4-day IQ pretreatment at 10/20/40 mg/kg i.p.; IEC-6 and Caco-2 cells underwent OGD/R in vitro. Network pharmacology, 16S rRNA microbiome sequencing, molecular docking, oxidative stress assays, Western blotting, and Nrf2 knockdown experiments were employed.
Study Limitations
All in vivo experiments used only male C57BL/6 mice, limiting generalizability across sexes and genetic backgrounds. No pharmacokinetic or bioavailability data in humans are provided, and no large-animal or clinical trial data exist to confirm translational relevance. The study is also purely preclinical with no direct comparison to established clinical interventions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.